Loading…
CO-AMILOFRUSE is a brand name for Furosemide (also known as Frusemide). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Co-amilofruse tablets are indicated where a prompt diuresis is required. It is of particular value in conditions where potassium conservation is important; congestive cardiac failure, nephrosis, corticosteroid therapy, oestrogen therapy. Ascites associated with cirrhosis.
Verbatim from this product's MHRA label. Tap a section to expand.
For oral administration Adults:
One or two tablets to be taken in the morning.
Children:
Not recommended for children under 18 years of age as safety and efficacy have not been established.
Elderly:
The dosage should be adjusted according to diuretic response; serum electrolytes and urea should be carefully monitored.
Adverse effects have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100; <1/10); uncommon (≥1/1,000;<1/100); rare (≥1/10,000;<1/1,000); very rare (<1/10,000); frequency not known (cannot be estimated from the available data).
Co-amilofruse Tablets 5/40 mg are generally well tolerated.
Blood and lymphatic system disorders Frequency not known:
Eosinophilia, haemoconcentration. Occasionally thrombocytopenia may occur. In rare cases, leucopenia and, in isolated cases agranulocytosis, aplastic anaemia or haemolytic anaemia may develop. Bone marrow depression has been reported as a rare complication and necessitates withdrawal of treatment.
Nervous system disorders Frequency not known:
Paraesthesia may occur. 3). Dizziness, fainting and loss of consciousness (caused by symptomatic hypotension) and headache.
Metabolism and nutrition disorders Frequency not known:
Serum calcium levels may be reduced; in very rare cases tetany has been observed. Blood cholesterol and blood triglyceride levels may increase during furosemide treatment. During long term therapy they will usually return to normal within six months.
Glucose tolerance may be impaired with furosemide. In patients with diabetes mellitus this may lead to a deterioration of metabolic control; latent diabetes mellitus may become manifest. As with other diuretics, electrolytes and water balance may be disturbed as a result of diuresis after prolonged therapy.
However, as treatment is continued, the serum potassium concentration may increase due to the later onset of action of amiloride, especially in patients with impaired renal function. g. where higher furosemide doses are administered to patients with normal renal function, acute severe electrolyte losses, although amiloride may contribute to the development or aggravation of metabolic acidosis.
Co-amilofruse should be discontinued before a glucose tolerance test. Co-amilofruse should be used in caution in elderly patients or those with potential obstruction of the urinary tract or disorders rendering electrolyte balance precarious.
Urinary output must be secured. g. in prostatic hypertrophy, impairment of micturition), are at increased risk of developing acute urinary retention and require careful monitoring. 3). Particularly careful monitoring is necessary in elderly or seriously ill patients and those with: • Hypotension • those at risk from a pronounced fall in blood pressure.
g. 8). Cautious dose titration is required. • symptomatic hypotension leading to dizziness, fainting or loss of consciousness can occur in patients treated with furosemide, particularly in the elderly, patients on other medications which can cause hypotension and patients with other medical conditions that are risks for hypotension.
Caution should be observed in patients liable to electrolyte deficiency. Regular monitoring of serum sodium, potassium, creatinine and glucose is generally recommended during therapy; particularly close monitoring is required in patients at high risk of developing electrolyte imbalances or in case of significant additional fluid loss.
Hypovolaemia or dehydration as well as any significant electrolyte and acid-base disturbances must be corrected. This may require temporary discontinuation of Co-amilofruse. 73m2 body surface area as well as in cases where Co-amilofruse is taken in combination with certain other drugs which may lead to an increase in potassium levels.
In patients who are at high risk for radiocontrast nephropathy, furosemide is not recommended to be used for diuresis as part of the preventative measures against radiocontrast induced nephropathy. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take this medicine.
Hypersensitivity to furosemide, amiloride, sulphonamides or sulphonamide derivatives, or to any of the excipients of the product. 73m2 body surface area, anuria or renal failure with anuria not responding to furosemide, renal failure as a result of poisoning by nephrotoxic or hepatotoxic agents or renal failure associated with hepatic coma, hyperkalaemia, severe hypokalaemia, severe hyponatraemia, concomitant potassium supplements or potassium sparing diuretics, precomatose states associated with cirrhosis, Addison’s disease, and breast feeding women.
Co-amilofruse is contraindicated in children and adolescents under 18 years of age as safety in this age group has not yet been established.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Furosemide in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Warning signs of electrolyte disturbances include increased thirst, headache, hypotension, confusion, muscle cramps, tetany, muscle weakness, disorders of cardiac rhythm and gastrointestinal symptoms. Disturbances of electrolyte balance, particularly if pronounced, must be corrected.
g. in decompensated cirrhosis of the liver) may be aggravated by furosemide treatment. Pseudo-Bartter syndrome may occur in the context of misuse and/or long-term use of furosemide. The diuretic action of furosemide may lead to or contribute to hypovolaemia and dehydration, especially in elderly patients.
As with other diuretics, treatment with furosemide may lead to increases in blood creatinine and blood uric acid, hyponatremia, hypochloremia, hypokalaemia, attacks of gout, hypocalcemia, hypomagnesemia and increased blood urea. g. nephrotic syndrome) and/or when intravenous furosemide has been given too rapidly.
- Tinnitus Frequency uncommon: Cases of deafness, sometimes irreversible, have been reported after administration of furosemide. Vascular disorders Frequency not known: - Furosemide may cause a reduction in blood pressure which, if pronounced may cause signs and symptoms such as impairment of concentration and reactions, light-headedness, sensations of pressure in the head, headache, dizziness, drowsiness, weakness/tiredness, disorders of vision, dry mouth, orthostatic intolerance.
- Thrombosis - Vasculitis Hepatobiliary disorders Frequency not known: In isolated cases, intrahepatic cholestasis, an increase in liver transaminases or acute pancreatitis may develop.
Skin and subcutaneous tissue disorders Frequency not known:
The incidence of allergic reactions, such as skin rashes, photosensitivity, vasculitis, fever, interstitial nephritis, or shock is very low, but when these occur treatment should be withdrawn. g. itching, urticaria, other rashes or dermatitis bullous lesions, erythema multiforme, bullous pemphigoid, exfoliative dermatitis, purpura, photosensitivity, Stevens- Johnson syndrome, toxic epidermal necrolysis, AGEP (acute generalized exanthematous pustulosis) and DRESS (Drug rash with eosinophilia and systemic symptoms), lichenoid reactions.
Psychiatric disorders Frequency not known:
Rare complications may include minor psychiatric disturbances.
Renal and urinary disorders Frequency not known:
Increased production of urine may provoke or aggravate complaints in patients with an obstruction of urinary outflow. Thus, acute retention of urine, associated with increased levels of sodium and chloride in urine with possible secondary complications may occur.
For example, in patients with bladder emptying disorders, prostatic hyperplasia or narrowing of the urethra. Nephrocalcinosis/nephrolithisasis has been reported in premature infants. Tubulointerstitial nephritis Renal failure Reproductive system and breast disorders Frequency not known: If furosemide is administered to premature infants during the first weeks of life, it may increase the risk of persistence of patent ductus arteriosus.
g. with shock) occur rarely. Exacerbation or activation of systemic lupus erythematosus.
Gastrointestinal disorders Frequency not known:
Side-effects of a minor nature such as nausea, malaise or gastric upset (vomiting or diarrhoea) and constipation may occur but are not usually severe enough to necessitate withdrawal of treatment. Pancreatitis acute Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the […]
1%; mean age 80 years, range 6790 years). Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings. No pathophysiological mechanism has been identified to explain this finding and no consistent pattern for cause of death observed.
Nevertheless, caution should be exercised and the risks and benefits of this combination or cotreatment with other potent diuretics should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other diuretics as concomitant treatment with risperidone.
3 Contraindications). The possibility exists of exacerbation or activation of systemic lupus erythematosus. Co-amilofruse contains Sunset yellow aluminium lake (E110) which may cause allergic reactions.